Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings (PASH)
2026年5月27日 更新者:Chen Dayu、The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings: A Randomized Clinical Trial
To analyse the efficacy of different preoperative prophylactic antimicrobial regimens for perioperative infection prevention in patients undergoing hepatobiliary surgery in a high antimicrobial resistance setting.
研究概览
详细说明
Given the high incidence of postoperative surgical site infections (SSI) potentially attributable to bacterial antimicrobial resistance, the use of beta-lactam/beta-lactamase inhibitor combinations for prophylaxis may reduce SSI rates following hepatobiliary surgery in the current era of high antimicrobial resistance.
To test this hypothesis, we propose a prospective pragmatic trial comparing piperacillin-tazobactam with the standard prophylactic regimen of cefuroxime for perioperative infection prevention in patients undergoing hepatobiliary surgery.
研究类型
介入性
注册 (估计的)
378
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Dayu Chen, Pharmacist in Charge, PharmD
- 电话号码:+86-025-83106666-60924
- 邮箱:cdy_pharmacy@njglyy.com
学习地点
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- 招聘中
- Nanjing Drum Tower Hospital
-
接触:
- Yao Du, Pharmacist in Charge
- 电话号码:+86-025-83106666-60910
- 邮箱:dudu0083@126.com
-
首席研究员:
- Dayu Chen, PharmD
-
首席研究员:
- Yao Du
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Adult patients aged ≥18 years;
- Deemed eligible for elective hepatobiliary surgery;
- Demonstrated comprehension of the study nature and expressed willingness to comply with trial procedures;
- Capable of providing written informed consent.
Exclusion Criteria:
- History of β-lactam allergy or hypersensitivity
- Uncontrolled preoperative infection;
- Current or recent (within the preceding month) systemic corticosteroid administration;
- Severe hepatic or renal impairment;
- Pregnancy or lactation;
- Concurrent enrolment in another clinical trial;
- Any other condition deemed by the investigator to render the patient unsuitable for study participation.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:控制组
|
|
|
实验性的:Intervention Group
Participants were randomized allocated to intervention group and receive piperacillin-tazobactam as prophylactic antibiotic before hepatobiliary surgery.
|
Participants were randomized allocated to intervention group and receive piperacillin-tazobactam as prophylactic antibiotic before hepatobiliary surgery.
Participants in the cotrol group will receive cefuroxime for prophylactic antibiotic.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with surgical site infection within 30 days after surgery
大体时间:30 days after the surgery
|
The primary endpoint, overall SSI rate, is defined as superficial incisional SSI, deep incisional SSI, or organ/space SSI within the first 30 days after the operation, as defined according to the ACS NSQIP data collection operations manual.
|
30 days after the surgery
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
30-day mortality
大体时间:30 days after the surgery
|
30 days after the surgery
|
|
|
Number of Participants with Sepsis within 30 days after surgery
大体时间:30 days after the surgery
|
Sepsis was defined according to criteria of the third international consensus of sepsis (doi: 10.1001/jama.2016.0287).
|
30 days after the surgery
|
|
Number of Participants with Postoperative bile leak or pancreas fisula
大体时间:30 days after surgery
|
Postoperative bile leak and pancreas fisula was assessed by the treating surgeons.
|
30 days after surgery
|
|
Postoperative hospital stay
大体时间:Length of postoperative hospital stay from date of surgery until the date of first documented date of discharge from any cause, whichever came first, assessed up to 90 days.
|
Length of postoperative hospital stay from date of surgery until the date of first documented date of discharge from any cause, whichever came first, assessed up to 90 days.
|
|
|
Number of participants with infections other than surgical site infection
大体时间:Other infections occurred within 30 days after surgery.
|
Infection was assessed by the treating surgeons.
|
Other infections occurred within 30 days after surgery.
|
|
Number of Participants with unplanned readmission and secondary surgery
大体时间:Unplanned readmission and secondary surgery within 30 days after surgery.
|
Unplanned readmission and secondary surgery within 30 days after surgery.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年5月24日
初级完成 (估计的)
2028年12月31日
研究完成 (估计的)
2029年1月31日
研究注册日期
首次提交
2026年5月21日
首先提交符合 QC 标准的
2026年5月27日
首次发布 (实际的)
2026年6月2日
研究记录更新
最后更新发布 (实际的)
2026年6月2日
上次提交的符合 QC 标准的更新
2026年5月27日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 2026-0252-02, 2026-0452-03
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
在美国制造并从美国出口的产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.